Election Year Impact: What's at Stake for Drug Pricing Reform
340B Now
From explosive growth in drug purchases to major hospital chains entering the space, this episode dives into the forces that could reshape 340B healthcare policy and pricing. We analyze how the 2024 election could transform drug pricing reform, backed by fresh data on state-level legislation and bipartisan movements. Hear critical insights on Johnson & Johnson's controversial rebate model proposal, HRSA's forceful response, and what these shifts mean for healthcare providers and pharmacies. Plus, we break down why traditional penny pricing is disappearing and what that signals for the industry's future. Essential listening for healthcare executives navigating this rapidly evolving landscape.